Shideh Roshani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shideh Roshani has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Antonella Naddaf
Department of Biology, Faculty of Sciences, Lebanese University, Lebanon
1 shared publication - Emre Hamurtekin
Department of Pharmacology, Faculty of Pharmacy, Eastern Mediterranean University, 99628 Famagusta, Türkiye
1 shared publication - Fatima Serhan
Department of Biology, Faculty of Sciences, Lebanese University, Lebanon
1 shared publication - Hala Gali-Muhtasib
Department of Biology, American University of Beirut, Beirut, Lebanon
1 shared publication - Hala Khalifeh
Faculty of Sciences I
1 shared publication - Imge Kunter
Faculty of Pharmacy, Eastern Mediterranean University
1 shared publication
Latest Publications
- Open Access
- 3 March 2025
- Published by MDPI AG in Preprints.org
Htlv-1, a Virus with Oncogenic Potential: Mechanisms, Treatment and Challenges
More than three decades have passed since adult T-cell leukemia/lymphoma (ATL) was first identified as a distinct disease in Japan. During this time, researchers discovered its causative agent—the human T-cell leukemia virus type 1 (HTLV-1). HTLV-1 infection has a significant global prevalence, affecting an estimated 5–10 million individuals worldwide. In this review, we provide a comprehensive overview of HTLV-1 persistence, latency, replication, and oncogenesis, with a particular focus on the roles of viral proteins such as Tax, HBZ, Rex, p30, p12, and p8. Understanding these mechanisms is essential for developing effective therapeutic strategies against HTLV-1-associated diseases, including ATL. Additionally, we explore current treatment strategies for ATL, including conventional chemotherapy, allogeneic hematopoietic cell transplantation, and epigenetic therapies. Gaining deeper insights into HTLV-1 pathogenesis, its molecular drivers and the existing therapeutic approaches can pave the way for more refined and innovative strategies to combat HTLV-1-associated malignancies.
- 3 March 2025
- Published by MDPI AG in Preprints.org
Open AccessHtlv-1, a Virus with Oncogenic Potential: Mechanisms, Treatment and Challenges
More than three decades have passed since adult T-cell leukemia/lymphoma (ATL) was first identified as a distinct disease in Japan. During this time, researchers discovered its causative agent—the human T-cell leukemia virus type 1 (HTLV-1). HTLV-1 infection has a significant global prevalence, affecting an estimated 5–10 million individuals worldwide. In this review, we provide a comprehensive overview of HTLV-1 persistence, latency, replication, and oncogenesis, with a particular focus on the roles of viral proteins such as Tax, HBZ, Rex, p30, p12, and p8. Understanding these mechanisms is essential for developing effective therapeutic strategies against HTLV-1-associated diseases, including ATL. Additionally, we explore current treatment strategies for ATL, including conventional chemotherapy, allogeneic hematopoietic cell transplantation, and epigenetic therapies. Gaining deeper insights into HTLV-1 pathogenesis, its molecular drivers and the existing therapeutic approaches can pave the way for more refined and innovative strategies to combat HTLV-1-associated malignancies.